Cellular Biomedicine Group to Present at ChinaBio(R) Partnering Forum in Shanghai on April 16, 2015
April 10 2015 - 9:30AM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the
"Company"), a biomedicine firm engaged in the development of
effective treatments for degenerative and cancerous diseases,
announced that they have been selected to present at the seventh
annual ChinaBio® Partnering Forum 2015 to be held in Shanghai
(April 15–16, 2015) at the Kerry Hotel Pudong in Shanghai, China.
This life science industry event is expected to attract over 800
attendees from around the world focused on developing cross-border
relationships in China.
Companies were selected to present based on their products,
technologies or services providing high-value to multinational or
domestic companies doing business in China. William (Wei) Cao, PhD,
BM, Chief Executive Officer of the Company, will present
"Realizing the Potential of Cell-Based
Therapy Technology" on April 16th at 3:15pm.
Cellular Biomedicine Group will be available during the event
for one-to-one meetings scheduled via EBD Group's partneringONE®
system, and the Company's exhibition space can be found at booth
1101.
More information on the ChinaBio® Partnering Forum is available
at www.CBPF2015.com.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. Our developmental stem cell, progenitor cell, and
immune cell projects are the result of research and development by
scientists and doctors from China and the United
States. Our flagship GMP facility in China, consisting of eight
independent cell production lines, is designed, certified and
managed according to U.S. standards. To learn more about
CBMG, please visit: www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Sep 2023 to Sep 2024